Retatrutide vs Setmelanotide
Head-to-head comparison of Retatrutide and Setmelanotide for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Retatrutide | Setmelanotide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / MC4R Agonist |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). | Setmelanotide is a selective MC4R agonist that re-establishes signaling in the hypothalamic leptin-melanocortin pathway. |
| Evidence Rating | B — Phase III / NDA Filed | A — FDA Approved |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | FDA-approved (Imcivree, November 2020 for POMC/PCSK1/LEPR deficiency obesity; June 2022 for BBS obesity) |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common (>=10%): injection site reactions (45%), skin hyperpigmentation (75%, due to MC1R activation), spontaneous penile erections in males (~38%), GI effects (nausea, diarrhea, abdominal pain); Skin hyperpigmentation: occurs in most patients due to MC1R agonism. Typically darkening of existing skin and nevi. Dermatologic monitoring recommended. |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous injection |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | 1-3 mg once daily depending on age and response |
| Frequency | Once weekly | Once daily |
| Molecular Weight | N/A | ~1117.3 g/mol |
| Half-Life | ~6 days (allows once-weekly dosing) | ~11 hours |
Overview
Retatrutide and Setmelanotide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Setmelanotide — Mechanism & Evidence
Setmelanotide (brand name Imcivree) is a cyclic 8-amino-acid peptide (MW ~1117.3 g/mol) that acts as a melanocortin 4 receptor (MC4R) agonist. It was subsequently approved for Bardet-Biedl syndrome (BBS) in June 2022. Setmelanotide directly restores MC4R signaling downstream of the defective leptin-melanocortin pathway.
Key claims: Significant weight loss in POMC deficiency obesity; Effective in LEPR deficiency obesity; Reduces hyperphagia in Bardet-Biedl syndrome.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Setmelanotide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Setmelanotide: Common (>=10%): injection site reactions (45%), skin hyperpigmentation (75%, due to MC1R activation), spontaneous penile erections in males (~38%), GI effects (nausea, diarrhea, abdominal pain) Skin hyperpigmentation: occurs in most patients due to MC1R agonism. Typically darkening of existing skin and nevi. Dermatologic monitoring recommended. Spontaneous erections and sexual adverse effects: common in males due to central melanocortin signaling. Generally decrease over time.
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe